Zolbetuximab: Clinical Development of Claudin 18.2 Monoclonal Antibodies
Time: 9:00 am
day: Conference Day 1
Details:
- Exploring Zolbetuximab, a monoclonal antibody targeting claudin 18.2, and its application in treating metastatic gastric cancer
- Reviewing a detailed presentation on clinical trial outcomes, including efficacy, safety, and the impact on progression-free survival and overall survival rates
- Integrating Zolbetuximab into standard treatment regimens and its potential for combination with other therapeutic modalities
